| Literature DB >> 30772098 |
Alan Menter1, Bruce E Strober2, Daniel H Kaplan3, Dario Kivelevitch1, Elizabeth Farley Prater4, Benjamin Stoff5, April W Armstrong6, Cody Connor7, Kelly M Cordoro8, Dawn M R Davis9, Boni E Elewski7, Joel M Gelfand10, Kenneth B Gordon11, Alice B Gottlieb12, Arthur Kavanaugh13, Matthew Kiselica14, Neil J Korman15, Daniela Kroshinsky16, Mark Lebwohl12, Craig L Leonardi17, Jason Lichten14, Henry W Lim18, Nehal N Mehta19, Amy S Paller20, Sylvia L Parra21, Arun L Pathy22, Reena N Rupani17, Michael Siegel14, Emily B Wong23, Jashin J Wu24, Vidhya Hariharan25, Craig A Elmets7.
Abstract
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.Entities:
Keywords: biologic agents; clinical guidelines for psoriasis; dermatology; guidelines; monoclonal antibodies; psoriasis; skin disease
Mesh：
Substances：
Year: 2019 PMID： 30772098 DOI： 10.1016/j.jaad.2018.11.057
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527